InMed Pharmaceuticals Inc. (FRA:MWG)

Market Cap	3.66M +19.9%
Revenue (ttm)	4.09M -3.3%
Net Income	-7.00M
EPS	-1.77
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	0.8600
Previous Close	0.9300
Day's Range	0.8600 - 0.8600
52-Week Range	0.8500 - 6.6000
Beta	n/a
RSI	40.79
Earnings Date	Feb 5, 2026

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids ...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MWG

Financial Performance

In fiscal year 2025, InMed Pharmaceuticals's revenue was $4.94 million, an increase of 7.50% compared to the previous year's $4.60 million. Losses were -$8.16 million, 6.34% more than in 2024.

Financial numbers in USD